Clinical Trials Browser

Recurrence × Panobinostat × Lymphoid × Clear all

NCT00936611 2021-01-28

LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

Phase 2 Completed

39 enrolled 13 charts

Waldenstrom Macroglobulinemia, Recurrence

NCT01032148 2017-01-12

Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma

Phase 1 Terminated

Hodgkin Disease, Lymphoma, Non-Hodgkin, Recurrence

NCT00978432 2016-11-25

Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Terminated

50 enrolled 11 charts

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01321346 2015-11-24

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

Phase 1 Completed

LymphoidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Leukemia, Myeloid, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00967044 2015-02-26

Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma

Phase 1/2 Completed

31 enrolled 6 charts

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence

NCT01090973 2013-12-16

Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Phase 2 Terminated

1 enrolled 6 charts

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell